|Publication number||US3809294 A|
|Publication date||May 7, 1974|
|Filing date||Jun 27, 1973|
|Priority date||Jun 27, 1973|
|Also published as||CA1043208A, CA1043208A1, DE2415360A1, DE2415360C2|
|Publication number||US 3809294 A, US 3809294A, US-A-3809294, US3809294 A, US3809294A|
|Original Assignee||American Cyanamid Co|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (2), Referenced by (85), Classifications (15)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent r191 Torgeson [451 May 7,1974
[ DISPENSING LUNG CONTACTING POWDERED MEDICAMENTS  Inventor: William Lee Torgeson, Minneapolis,
 Assignee: American Cynamid Company,
 Filed: June 27, 1973  Appl. No.: 374,176
 U.S. Cl.,..' 222/182, 128/203, 128/208,
- 222/4022  Int. Cl .L A61m 15/02  Field of Search... 222/182, 183, 4022}  References Cited UNITED STATES PATENTS Meshberg 128/203 3,559,851 2/1971 Steinman 222/222 Primary ExaminerRobert B. Reeves Assistant Examiner-Larry H. Martin Attorney, Agent, or FirmSamuel Branch Walker  ABSTRACT A combination aerosol container carrier and deceleration chamber carries an aerosol container in one configuration and in another dispenses powdered medicament from the aerosol container with inhaled particles predominantly below 10 microns in size at a low velocity which gives a comparatively high degree of topical effect in the lungs as compared with systemic effeet from powders .absorbed in the mouth. The lungs may be used as an effective administration route for systemic medicament effect.
3 Claims, 5 Drawing Figures PAIENTEMY 7 1974 SHEU 1 UP 2 IE. E
PATENTEDIAY new: 3.809.294
sum 2 or 2 DISPENSING LUNG CONTACTING POWDERED MEDICAMENTS BACKGROUND OF THE INVENTION The inhalation of medicaments has long been known. There is a continuing effort to secure uniform comparatively accurately measured dosages in selected areas. Large particles have a tendency to be deposited in the mouth or upper throat. Small particles, below about microns, have a tendency to go deeper intothe lungs. The problem is to secure the desired dose in the desired area of a desired medicament at the desired time.
. Sometimes the systemic effect. of a drug on other or- SUMMARY OF THE INVENTION The present inventionis based upon the discovery that the discharge from an aerosol container can be suspended in dry vaporized propellant mixed with air by theme of a deceleration chamber which is big enough to serve as a carrier for the aerosol container in a storage and transportation configuration and which has a neckeddown mouthpiece at one end and a neckeddown spray system at the other.
The deceleration chamber is about the same volume as the human oral cavity, with the mouth open. It serves to decelerate the aerosol charge to give a' low velocity to the dispersed powder, absorb the aerosol jet momentum before the suspended powder enters the users mouth, complete the vaporization of the aerosol propellant, eliminating the possibility of liquid propellant reaching the mouth, dilute, the propellant and suspended powder with air, and give uniform and acceptable powder losses, so that uniform doses are administered. It is desirable that a major portion of a discharged medicament be administered to the user, but it is more important that each dose be of consistent and predictable size and absorbability so that a known uniform dose is administered with each actuation of the actuation button. A considerable percentage of loss is acceptable if reliably uniform. With the present system, losses of about 25 to 50 percent of the total medicament doses occur. The deceleration chamber traps much of the medicament that would deposit in the mouth of the user, so that a relatively small amount of the medicament is deposited in the mouth as compared to the amount that reaches the lungs, and is effective in the lungs.
Additionally, a trap system is used to submerge the metering valve to insure that the metering valve is immersed in the propellant at all times so that the metering chamber does not drain and, in efiect, lose its prime. This at times is'referred to as a drain-free trap.
The system is. particularly adapted to the use of such drugs as triamcinolone acetonide and N,N-diethyl-4- methyl-l-piperazine carboxamide pamoate(diethylcarbamazine pamoate), both of which are of value in the treatment of asthma and both of which are desirably administered in small known uniform accurate dosages which are absorbed primarily in the lung system as con- 2 trasted with the nose and throat. The physiological effectiveness is augmented by the possibility of increasing the concentration of drugs administered to the desired location, as compared to that obtained when the drugs are administered systemically.
Some medicaments are conveniently administered by inhalation, for a systemic effect. Penicillin has been administered by inhalation,'as more convenient than by injection. Many drugs are absorbed through the lugs, if a suitable system of dispensing for inhalation is available. The inhalation of gases, such as ether, or liquids is much more common.
DESCRIPTION OF THE PRIOR ART Certain representative patents in this very crowded field include:
U. S. Pat. No. 2,533,065, Taplin and Bryan, Dec. 5, 1950, Micropulverized Therapeutic Agents shows the use of powdered penicillin, of a particle size of less than one micron, for inhalation therapy. The penicillin is disclosed as absorbed in the lungs with high efficiency.
U. S. Pat. Nos. 2,721,010, Meshberg, Oct. 18, 1955, Aerosol Containers And Valves Therefor," and US. Pat. No. 2,968,427, Meshberg, Jan. 17, 1961, Valve For Aerosol Container show metering valves for aerosol container. Small uniform charges of the contents are dispensed on each separate actuation.
Such valves, among others, may be used for metering doses for the present invention.
U. S. Pat..No. 2,992,645, Fowler, July 18, 1961, Disperser.ForPowders, in Column 2 has a table showing the effect of particle size on the zone of deposition of a powder in the respiratory tract. Powder sizes of 1 and 3 microns are shown to go deeply into the lungs.
U. S. Pat. No. 3,012,555, Meshberg, Dispensing Package For Material. Under Pressure' shows an aerosol liquid dispenser with an operating spray button assembled to the valve system, which button, with spray orifice, fits removably into an applicator nozzle. In one configuration the applicator nozzle is used for spray control; in another for protective storage.
U. S. Pat. No. 3,219,533, Mullins, Nov. 23, 1965, Aerosol Solid Medicament In Propellant And Low- Level Ethanol Avoiding Higher-Level Ethanol Dis Aerosol Apparatus, shows an aerosol liquid dispenser using coaxial concentric extendable tubes for particle size control. The tubes in collapsed position function as a container carrier for storage. In extended position, the mass of air in the tubes impedes the forward flow of a spray and serves as a partial barrier to the discharge jet. The inside diameter is preferably 18 to 30 mm. and the length 3 to 10 times the diameter, preferably 5 to 7 times.
The aerosol container and valve are taken out of the stored position, and the valve stem is inserted into a dispensing spray head which forms the end of the inner tube at the time of use.
Dec. '12, 1961,
Ramis teaches that for inhalation therapy, the particles of the therapeutic agent should be between 0.5 and microns in size, since particles above 5 microns may not reach the air-cells in the lungs while particles below 0.5 microns may fail to be deposited in the lungs. Ramis teaches using dichloro-difluoro-methane as the propellant in which the active product is dissolved or kept in a homogeneous-emulsion suspension. The disclosures are limited to soluble products. I
U. S. Pat. No. 3,727,806, Wilmot, Apr. 17, 1973, Valve Assembles For Aerosol Containers, shows a metering valve assembly in which a hollow member fits over the inner end of the valve stem and moves therewith to create a capillary gap to aid in avoiding wastage as the container contents become exhausted. This container is used in a valve down position.
U. S. Pat. No. 2,467,895, Kushner and Brancone,. Apr. 19, 1949, Piperazine Derivatives and Method of 'Co., Rahway, N. J. 1968), pages 1064 and 1065.
U. S. Pat, No. 3,457,350, Mallen, July 22, 1969, Method Of Treating Asthma, shows the use of N,N- diethyl-4-methyl-l-piperazinecarboxamide (commonly called diethylcarbamazine) for asthma. The dihydrogen citrate salt is disclosed specifcally.
SUMMARY OF THE INVENTION A dispensing package for therapeutic agents'under pressure such as shown in Meshberg, US. Pat. No. 3,012,555, supra, is modified by adapting a valve to dispense a powdered medicament suspended in the propellant and discharging the nozzle into the entrance of a decelerationchamber having a cylindrical barrel portion, a mouthpiece at the exit end, and container hOlder-tactuating button holder to hold the spray nozzle system.
Preferably, the deceleration and expansion chamber is adapted to completely enclose and hold the aerosol container during storage with the system being assembled in one configuration for storage and transportation and another for use. By having dust covers and sealing means, the assembly in storage and transportation position is protected from contaminating dust and may be conveniently carried in the pocket of a user and yet be rapidly assembled with minimum risk of contamination of the contents at the time of use.
Because some medicaments may be used only under conditions of stress or at irregular hours, it is highly advantageous that the assembly be completely protected in the storage and transportation configuration and readily and rapidly convertible to the dose administering configuration when medicament is to be administered. 0
Other advantages will be appreciated by those skilled in the art from the detailed description of the device.
DRAWINGS FIG. 1 is a pictorial view of the aerosol dispenser assembled in dose administering configuration.
FIG. 2 is a view in partial section showing the dispenser in the storage and transportation configuration.
FIG. 3 is enlarged view in section showing the valve assembled to the expansion chamber cover and particularly, an anti-drain tank to insure that the metering valve is continuously immersed in the propellant and, thus, protected from partial draining and resulting irregular dosages.
FIG. 4 shows the same valve assembly in compressed position after a dose in which the valve stem has been depressed.
FIG. 5 is a second configurationin which the'actuating button fits into a movable applicator nozzle for storage.
As shown in FIG. 1, the biggest element of the aerosol dispenser is the deceleration chamber 11, preferably of a plastic such as polyethylene. The deceleration chamber has a cylindrical barrel 12 which conveniently may be'about 2 94 inches in length and 1 A inches in internal diameter with a shell wall thickness of around one-sixteenth inch. At one end is a mouthpiece 13 conveniently about seven-eighths inch in outside diameter economical method of manufacture and a smooth, easily cleanable working surface. A mouthpiece cap 15 fits removably on the mouthpiece in dust excluding relationship. The cap may slide on either interiorly or exteriorly with a finger friction fit. The term finger friction fit is used to note a frictional relationship which will hold pieces together under normalhandling conditions, but may be readily disengaged or engaged by finger pressure only. The exterior-surface of the mouthpiece cap may be roughened or knurled for easier grasping by the fingers. The edges of the mouthpiece cap and the mouthpiece may be broken" or slightly rounded in accordance with conventional practice for ease in assembly, as may other edges. Either the mouthpiece or the mouthpiece cap may have small ribs of the order of' 0.002 inch to reduce friction and ease engagement. By
having such small raised portions or beads on frictionally engaging portions, the natural resilience of plastic such as polyethylene is utilized to give a frictional engagement which may be readily disengaged with the fingers without expensive requirements as to accuracy in sizing of the pieces. Similar assembly details may be used elsewhere. in the present dispenser, and are conventional in the plastics molding art.
At the open end of the cylindrical barrel 12 is a container holder 16. The container holder'is a multifunctional element. A holder flange 17 fits across the open end of the cylindrical barrel 12. A positioning sleeve 18 engages the end of the cylindrical. barrel 12. Conveniently, but not necessarily, the positioning sleeve fits interiorly'of the cylindrical barrel 12 with a friction fit and the positioning sleeve is long enough to, prevent acv 5 cidental disengagement but permit ready removal of the container holder 16. Conveniently, but not necessarily, the positioning sleeve 18 extends from the holder flange 17 so that its resilience permits finger frictional engagement with the normal accuracy of molding parts. A containerholding sleeve 19 extends interiorly from the holder flange l7 and is of a size to fit around, retain, and position an aerosol container 20. Conveniently, but not necessarily, the aerosol container 20 is of stainless steel or aluminum to hold high pressure aerosol propellants. The container holding sleeve is long enough and of a size to position and retain the aerosol container assembly inside and axially of the deceleration chamber 11 during storage and transportation phases of using the device, and permits ready disengagement from the aerosol container 20 at the time of administration.
Through the holder flange extend one or more-air vents 21 which provide for the introduction of diluent air during use. Three vents, each /8111Ch diameter, give good results. V
Extending exteriorly from the holder flange 17 is a button holder 22. The button holder is hollow, has a closed end opposite to the holder flange, and has therein an indexing port 23 which is of a size and shape to hold an aerosol actuating button 24, which is described in more detail below. Because the aerosol actuating button is to be oriented, the shape of the indexing port 23 is such as to match with the actuating button 24 and hold the actuating button in anoriented relationship. As shown, the actuating button is cylindrical with a flat side 25 whichflat side cooperates with an indexing port flat 26 so that the spray is directed axially of the deceleration chamber. Conveniently, but not necessarily, the button holder is formed with two indexing ports 23 in diametrically opposed relationship so that the actuating button 24 can be inserted from either side and the other port serves such as an additional air inlet. At the end of the button holder 22 away from the holder flange 17 is a retaining bead 27 which conveniently extends up about S/IOOOths of an inch above the exterior cylindrical surface of the button holder. A protective sleeve 28 fits in light frictional engagement over and on the exterior surface of the button holder. Being made of plastic, there is sufficient resilience that the protective sleeve 28 may be easily forced over the retaining head 27 into position and is not readily removed so that it is retained in place during the useful life of the dispenser. The protective sleeve has button apertures 29 to permit the sleeve 28 to be rotated so that the button apertures 29 index with the indexing ports and permit the button to be inserted therethrough and yet can be rotated through about 90 to protect the assembly from the entrance of dust and dirt during storage and transportation.
In FIG. 2 is shown the dispenser in the carrying configuration for storage and transportation in which the container 20 is removed from the container holding sleeve 19, the protective sleeve 28rotated until the button apertures 29 index with the indexing port 23, and assembled in dose administering configuration by inserting the actuating button 24 through the button aperture 29 into one of the indexing ports 13 so that the spray port 32 is axial and concentric with the cylindrical barrel 12 of the deceleration chamber, so that the discharge from the aerosol container is symmetrical with respect to the deceleration chamber.
As shown in FIG. 3, in the dose administering position the aerosol container 20 extends upwards so that the medicament in propellant 33 is drawn by gravity against the valve assembly 30.
The actuating button '24 has a spray port 32.which is conveniently counterbored into the button and has a spray orifice 34 through which the medicament in propellant is discharged. This spray orifice may either be formed integral with the spray button or a separate metallic insert may be used. Both are conventional constructions. The spray orifice should have a diameter such that the discharged dose is disbursed in finely divided form as a cone on exit from the spray orifice.
An orifice of about 0.015 to 0.018 inch gives a good spray pattern. a
The actuating button- 24 fits snugly on the end of a valve stem 35 which extends into the valve body 36. The valve body 36 has therein a metering chamber 37 in which the valve stem 35 is slidably mounted. Between the valve body and the ferrule 31 is a metering gasket 38 which performs the dual function of serving as a seal against loss of propellant when the valve stem collar 39 presses against the metering gasket, and acts as a ring seal around the valve stem 35 so that as the valve stem is depressed against the valve spring 40, the metering port 41 in the valve stem passes the metering gasketand permits the contents of the metering chamber to pass through the metering port 41, the axial valve stem bore 42, extending throughthe valve stem, into the discharge passage 43 in the actuating button'24 to the spray orifice 34. At the inner end of the valve stem 35 are charging flutes 44. These cooperate with a charging gasket 45 which is held against the lower end of the metering chamber by a stainless steel valve stem washer 46 which, in turn, isheld against the bottom of the metering chamber 37 by the valve spring 40. In operation, as the valve stem 35 is depressed, the
' valve stem 35 passes through the charging gasket 45 so that the charging flutes pass through the charging gasket and the full diameter of the valve stem 35 sealsagainst the charging gasket 45 so that the metering chamber is filled and closed at the inner end before the metering port 41 passes the metering gasket 38 which permits the contents of the metering chamber to discharge through the. metering port 41, the axial valve stem bore 42, the discharge passage 43, and the spray orifice 34.
FIG. 4 shows the actuating button 24 in depressed position with the valve in the discharge position.
When pressure on the actuating button 24 is released, the valve stein 35 is pushed outwardly by the valve spring 40 so that the metering port 41 passes the metering gasket 38 which closes discharge from the metering chamber, and later the charging flutes 44 pass the charging gasket 45 permitting the propellant containing the medicament to flow through the charging flutes 44 and again fill the metering chamber 37.
The valve body 36 a valve body flange 47 which covers the end of'the aerosol container 20 and is sealed thereto by a container gasket 48. The ferrule 31 holds the assemblyin position against the end of the aerosol container 20 by the ferrule 31 being swaged against the stainless steel or aluminum aerosol container 20.
The above construction for a metering valve is one type of metering valve. Other conventional types of metering valves may be used.
Because the metering valve discharges a comparatively small charge; for instance about 50 microliters per actuation is a convenient commercial size, and each discharge has a volume of about that of a small drop of water, it is important that the metering chamber be completely filled before each actuation and that the metering chamber be prevented from draining back into the aerosol container between actuations. This loss of charge or loss of prime is prevented by an anti-drain tank 49. The anti-drain tank 49 fits into a flange sleeve 50 on the valve body flange 47 which flange sleeve 50 has an interior cylindrical surface against which the anti-drain tank 49 is asnug friction fit. In the periphery of the anti-drain tank 49 and between the anti-drain tank and the flange sleeve 50 is a charging'passageSl which provides for refilling of the anti-drain tank from the main body of the medicament in propellant in the aerosol container. 4 I
To protect against accidental disengagement of the anti-drain tank as, for example, by dropping the aerosol container on the floor during use, the anti-drain tank is sonically welded into position using an ultrasonic seal in which ultrasonic energy is passed through the flange sleeve to the anti-drain tank. As the energy passes through, there is a discontinuity between'the anti-drain tank and the flange sleeve so that energy is reflected and refracted causing dissipation of ultrasonic energy which reappears as heat which melts and thereby seals the anti-drain tank to the flange sleeve. By such ultrasonic sealing, the assembly is economical and effective. When so sealed, the anti-draintank remains in position under any use or abuse that does not damage the aerosol container itself.
Because of the nature of the propellant composition, when the actuating button is depressed with the aerosol container in dispensing position, the contents of the metering chamber are discharged and as the actuating button is released, a new charge is drawn from the antidrain tank into themetering chamber and the antidrain tank is refilled through the charging passage 51.
The anti-drain tank remains filled with the propellant containing the medicament independent of the orientation of the aerosol container. Thus, a predictable, uniform, accurate dosage is dispensed with each actuation of the actuating button. 1
By keeping the fluted end of the valve stem immersed in liquid propellant at all times, the homogeneity of the solid finely divided medicament in the propellant is maintained more uniformly, and more consistent uniform doses are dispersed. The use of a plstic anti-drain tank appears to aid in neutralizing electrical charges which would otherwise build up in the system. With a stainless steel aerosol container 20, the periphery of the propellant charge is effectively at a single potential, but the propellant can act as a dielectric so that the individual particles of medicament become charged and affect their dispersion and discharge-rate. With the an-' ti-drain tank, the effect of the stainless steel container is at least in part neutralized so that static effects are reduced or minimized permitting more uniform charge characteristics. 7
In the absence of the anti-drain tank, the first 25 percent of discharge doses are found to be higher than the last 25 percent so that the user is receiving more medi-, cation than anticipated from the new dispenser and less than anticipated from the nearly empty dispenser. With the present anti-drain tank, the variation in charges are minimized so that the user is obtaining a more reliably uniform dosage of the medicament.
It is difiicult to measure the effect of electrical charges within the aerosol container and in the deceleration chamber but independent of the theoretical and scientific background for explaining uniformity of charge, it is found that with the present anti-drain tank, more uniform dosages are dispensed and with the deceleration chamber in which the mouthpiece has less than half the cross sectional area of the cylindrical barrel, and the length of the cylindrical barrel is less than twice its diameter, the individual dosages of medicament in propellant are dispersed into the deceleration chamber and lose the jet velocity imparted by the propellant spray. If any particles still retain velocity, they either impinge or are retained by the walls of the deceleration chamber or are bounced away from the walls so that a dispersed powder charge is formed which is mixed with additional diluent air and inhaled, as the user inhales the finely divided medicament through the mouthpiece. A large portion of the medicament which would otherwise be deposited in'the mouth of the userand, hence, absorbed systemically, are deposited on the walls of the deceleration chamber.
Even though the medicament may be fairly expensive, the dosages are so small that about a 25 to 50 percent loss in the deceleration chamber is a highly acceptable loss as compared with the advantages of consistency and uniformity of the dose which is administered to the patient.
With many drugs it is veryimportant that the desired quantity be administered to the user. Uniformity is important so that the physician administering knows what adjustments in dosage level need be made depending on the response of the user.
In FIG. 5 is shown a modification of the aerosol dispenser system in which the container holding sleeve of the type shown in Meshberg, U.S. Pat..No. 3,012,555, supra, is used with an applicator nozzle 52 fitting in the holder flange 53 with the bottom end of the aerosol container fitting into the applicator nozzle. Slidably fitting in the other end of the applicator nozzle is a button holding slide 54 which can be pressed inward for sealing or pulled'outward to hold the actuating button in operating position. The details of this construction are shown in said U.S. Pat. No. 3,012,555.
Other configurations can be used providing that the deceleration chamber is large enough to decelerate the dispensed aerosol charge and permit the inhalation velocity from the inhalation of the user to be the sole factor in controlling the rate of administration at the time of use. With a metering trap holding about 50 microliters of material, the energy of discharge is completely dissipated in the deceleration trap and a fine aerosol, almost a smoke, is formed of the drug to be administered, and this fine aerosol is inhaled into the lungs.
A smoke is normally defined as a suspension of fine solid particles in a gas such as may be produced by a fire with the particle sizes being in the colloidal range. Here the particle sizes range from an overlap of the colloidal range at the small end to slightly larger than a true colloid. The definitions as to particle size ranges are somewhat overlapping.
For Applicants purpose, a particle size range from about 0.5 microns to microns gives good results. Particleslarger than about 10 microns are too apt to be deposited in the mouth or the throat of the user to be preferred for inhalation therapy. A few particles in this size range are usually not deleterious, but contribute disproportionately to systemic absorption rather than through the lungs.
In use, because part of the medicament deposits on the walls of the deceleration chamber, the chamber sure propellant system is preferred. Dichlorodifluoromethane (Freon l2) which has a pressure'of about 80 pounds per square inch absolute at room temperature gives good results. A stainless steel or aluminum container is preferred for such pressures to avoid damage from breakage. Glass containers, or plastic containers, or a plastic covered and protected glass container may be used, but these are more conventional at lower pressures, of theorder of 30 to 50 pounds per square inch gage.
A plastic valve stem is preferred to metal, as the plastic valve stem'is less subject to binding or sticking from powder being packed around it. A small amount of a]- cohol, about 1 to 10 percent, functionsas a lubricant to keep valve action reliable. Some medicament in propellant systems function reliably without a lubricant.
Obviously, the size of the container and the size of the metering chamber can vary widely depending upon the dosage desired'for actuation, and the number of 'doses desired to be given to a patient for administration.
. Certain medicaments which may be effectively administered are illustrated by the following examples.
. EXAMPLE I DiethylcarbamazinePamoate Repetition of this procedure, with the exception that the sodium pamoate is added as an aqueous solution rather than a dry powder, results in the immediate precipitation of an amorphous solid that gradually crystallizes over a 2 day period. The solid is collected and air dried yielding 2.7 gm, M.P. 215220C. with decomposition. Calculated: C, 67.44; H, 6.35; N, 7.15 Found: C, 66.90; H, 6.26; N, 7.05
EXAMPLE II Diethylcarbamazine Pamoate From Pamoic Acid y filtered through diatomaceous earth. The cake' is washed with three 2 liter portions of methanol. The filtrate and washes are charged in a 100 gallon glass lined kettle, 21 liters of water added, and 10.9 liters (130 moles) of concentrated hydrochloric acid is added fairly rapidly. A bright yellow solid precipitates immediately. Stirring is continued at room temperature for l k hours. Free pamoic acid is recovered by filtration and washed with three 20 liter portions of water. The cake is slurried with about 80 liters of water for 1 hour, solids filtered off, the solids washed with three 2 liter portions of water and then with three 4 liter portions of methanol. The solid is then dried for 2 days at 5055C. The crude pamoic acid (11.8 Kg.) is dis- 1 solved in 61 liters of dimethylformamide at 85-90C. Two pounds of diatomaceous earth are added and the mixture is stirred for one-half hour before filtering,
through pre-heated funnels. The cake is washed with three 3 liter portions of dimethylformamide. The filtrate is added to 70 liters of water in a 50 gallon glass lined kettle. An additional 20 liters of water is added and the resulting mixture is stirred for 1 12 hours while being cooled to below 25C. The purified pamoic acid is filtered off, pressed dry and then washed with three 6 liter portions of water followed by three 4 liter portions of methanol. The pamoic acid is dried to a constant weight of 10.8 Kg. 86 percent based on 95 percent real starting disodium salt).
A l0.l Kg. (25.8 moles) portion of diethylcarbamazine dihydrogen citrate is dissolved in 80 liters of water and the solution is filtered.
A 1.96 Kg. (49.0 moles) portion of sodium hydroxide is dissolved in 100 liters of water and 10.0 Kg. (25.8 moles) of purified pamoic acid, prepared as described in this example, is added. The pamoic acid-sodium hydroxide mixture is stirred for one-half hour, -2 pounds of diatomaceous earth is added, stirring is continued for 1 hour and the mixture is clarified by filtration.
The filtrate is charged in a gallon glass lined kettle, stirred and the diethylcarbamazine citrate solution is added as rapidly as convenient. A very thick creamcolored precipitate forms immediately. Forty liters of water is added. After 1 hour of stirring thev mixture thins out considerably. Stirring is continued for l more hour. The product is collected by filtration and washed with three 15 liter portions of water. The material is dried at 50-55C., and then micro-milled twice in a fluid energy mill to give 13.5 Kg. of product. A 10.8 Kg. portion of this diethylcarbamazine pamoate is dissolved in a mixture of 25 liters of dimethylsulfoxide and-50 liters of methanol at 65C. The hazy solution is filtered through diatomaceous earth and the cake is washed with three 4 liter portions of methanol. The filtrate and washes are charged in a 50 gallon glass lined kettle and warmed to dissolve any separated material. Forty liters of methanol are added and the solution is chilled to and maintained at 0 (E4C. overnight. The product is fil rified pamoic acid in 400 ml of acetone heated to 50C.
there is added 53.0 gm (0.27 mole) of diethylcarbamazine dihydrogen' citrate. The resulting clear yellow solution is allowed to cool to room temperature and is then filtered. The filtrate is concentrated to dryness in vacuo at 50C. and the resulting product is dried in vacuo at 7580C. for 16 hours yielding 102.0 gm of bis-(N,N-diethyl-4-methyl-l-piperazine carboxarnide) pamoate as a yellow amorphous powder, M.P. ll105C. Analysis: Calculated: C,65.62; H, 7.44; N, 10.68 C H N O (787) Found: C, 65.22; H, 7.79; N, 10.80
EXAMPLE IV N, N-diethyl-4-methyl-l-piperazinecarboxamide pamoate was passed through a fluid energy pulverizing mill and micronized to 0.5 to 10 microns, with 90 percent by weight being in the range of l to 5 microns. 300 milligrams thereof in dry form where introduced into a 10 milliliter stainless steel container adapted to be fitted with an aerosol metering spray nozzle, and thereto was added 0.75 grams of anhydrous ethanol. Chilled (40C) dichlorodifluoro methane was added from a pressure tank to the open container which by evaporative cooling rapidly chilled the container and its contents, enough beingadded that the container held grams of dichlorofluoromethane, after which the container was closed with a metering valve, and the metering valve sealed in place.
A metering valve was used which discharged 50 microliters of contents per actuation which gives 1.3 milligrams of N,N-diethyl-4-methyl-l-piperazinecarboxamide pamoate per actuation with 65 milligrams of dichlorofluoromethane and 3.25 milligrams of ethanol being simultaneously dispensed. These are volatile and become mixed with. enough air so as to have minimal or no physiological activity.
Depending upon the degree of severity of an asthmatic attack, one or more actuations inhaled bring relief. The inhalation administration gives a rapid and 'ef- Because the diethylcarbamazine pamoate is adminis- 6 tered directly to the lungs, a smaller dosage, as the diethylcarbamazine, is normally required for effective relief than if administered systemically, i.e., orally, with 12 I the circulator system being utilizedto carry the medicament to the lungs.
EXAMPLE V Triamcinolone acetonide Triamcinolone acetonide was micronized in a fluid energy mill until percent by weight was in the particle size range of l to 5 microns.
A 19 ml. stainless steel container had charged thereto 30 mg. of the micronized triamcinolone acetonide, 0.244 ml. of anhydrous ethanol and was cold filledwith 19.5 grams of dichlorodifluoromethane at 40C, evaporation serving to chill the container, and an excess being added to allow for evaporation. The filled containers were closed with a metering valve, as above described, and sealed. Dispersion in the propellant is improved when the filled containers are immersed in an ultrasonic bath that transfers energy .from' the transducer to the contents of the aerosol container.
Good results are normally obtained by shaking to disperse the triamcinolone acetonide in the system. Ultrasonic dispersal is a refinement to insure more uniform dispersion in micronized form. I
The components can be mixed, treated ultrasoni cally, and pressure filled. Pressure f lling 'is more complex for small scale runs, but often preferred for large size runs, and saves loss of the propellant. The valve needs to be specifically designed for such pressure fill.
Each actuation of the valve button delivers about 0.1 mg. of triamcinolone acetonide. Five actuations four times a day gives a dosage of about 2 mg. of triamcinolone acetonide. As a portion is retained in the deceleration chamber, and some is exhaled, slightly more than 1 mg. a day is administered for a typical patient. A systemic dose'for a patient is about 8 mg. The lower level and delivery to the preferred site is a major'advantage.
The patient should be instructed to actuate the button to release the medicament into the deceleration chamber, and to inhale so that only the inspired air imparts velocity to the particles being absorbed. The patient should hold the inspired dose for a'few seconds to permit absorption on lung surfaces before exhaling. A minor amount of the medicament is exhaled.
Wherein the propellant in the preceding example is dichlorodifluoromethane, other chlorofluoroalkanes and their mixtures may be used.
Other modifications the art. I
I claim: a
1. An aerosol dispenser for dispensing uniform dosages of a finely-divided powdered medicament suspended in a propellant at a low velocity in inhalable dry aerosol form in the particle size range of 0.5 to 10 microns, comprising a circular cylindrical container carrier and deceleration chamber consisting essentially of a cylindrical barrel, and, at one end thereof, a mouthpiece and a mouthpiece-to-chamber flare, the mouthpiece being adapted to fit into a human mouth, said mouthpiece being cylindrical, and positioned coaxial with the cylindrical barrel by said flare,
a mouthpiece cap, adapted to removably engage and close the mouthpiece indust excluding relationship,
are apparent to those skilled in and at the other end of said chamber a removable container holder, adapted to close the deceleration chamber in essentially air tight relationship, comprising a holder flange, adapted to fit in sealing relationship with the cylindrical barrel of said chamber, a container holding sleeve effectively coaxial and integral with theholder flange and of a size to hold a circular the holder aerosol container with a friction-fit, and a button holder coaxial with the holder flange with means to hold an actuating button on an aerosol container in indexed relationship to discharge axially with the deceleration chamber, in dose administering position,
means to close the button holding means in dust excluding relationship in a carrier configuration,
and a circular cylindrical aerosol container having a 14 dose metering valve having thereon an actuating button, which button fits into said button holding a means in a dispensing configuration and which container fits interiorly of the cylindrical deceleration chamber in a storage configuration.
2. The aerosol dispenser of claim 1 in which the base of the aerosol container fits into the container holding sleeve and the actuating button extends towards and is shielded by the mouthpiece cap, when in the storage and carrying configuration.
3. The aerosol dispenser of claim 1 in which the ferrule end of the aerosol container fits into the container holding sleeve, and the actuating button extends into the button holder, when in the storage and carrying configuration.
Patent No. 2 gnq pqu.
j UNITED STATES PATENT OFFICE-- 'CE'RTIFICATE 0F CORRECTION Dated May :7. 1974- Inventofls) wILLlAM LEE TORGESON It is certified that error appears in the aboverident ified patent (SEAL) Attest: McCOY M. GIBSON. 31%.; Arresting Officer and that said'Letters Patent are hereby corrected as shown below:
line 16, for "is" read if line 6,l for "holder" read holder -'--5 line for "plsfic" read plastic linel'Z, for the first "The" I read To line close space between "N," andi-f'll".
1111a 1051 16" read 19 I line for "absorptioh" read adsorption line .7, for "theholder", read the holder line for "the holder" read cylindrical gned and sealed this 3rd day of December 1974 c. MARSHALL DANNIT Commissioner of Pat ents F ORM PO-l 050 (10-69) 1 1 a I uscoMM-oc wan-bed Q .5. GQVIRIIIQI!" PRINTING OFFICE 2 Q. O-Sll-IJI'
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3012555 *||May 18, 1959||Dec 12, 1961||Philip Meshberg||Dispensing package for material under pressure|
|US3559851 *||May 27, 1969||Feb 2, 1971||Valve Corp Of America||Fully-emptying valve assemblage|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US3994421 *||Sep 29, 1975||Nov 30, 1976||American Cyanamid Company||Unitary therapeutic aerosol dispenser|
|US3998226 *||Sep 22, 1975||Dec 21, 1976||Edward G. Gomez||Inhalation device for encapsulated concentrates|
|US4114615 *||Dec 10, 1976||Sep 19, 1978||Aktiebolaget Draco||Aerosol inhalation device|
|US5040527 *||Dec 18, 1990||Aug 20, 1991||Healthscan Products Inc.||Metered dose inhalation unit with slide means|
|US5074294 *||Jun 21, 1989||Dec 24, 1991||Chiesi Farmaceutici S.P.A.||Device for dispensing metered amounts of aerosol for inhalation|
|US5186164 *||Mar 15, 1991||Feb 16, 1993||Puthalath Raghuprasad||Mist inhaler|
|US5598836 *||May 26, 1995||Feb 4, 1997||Healthscan Products, Inc.||Metered dose inhalation unit with slide means|
|US5653962 *||May 19, 1995||Aug 5, 1997||Glaxo Group Limited||Aerosol formulations containing P134a and particulate medicaments|
|US5658549 *||May 19, 1995||Aug 19, 1997||Glaxo Group Limited||Aerosol formulations containing propellant 134a and fluticasone propionate|
|US5674471 *||May 19, 1995||Oct 7, 1997||Glaxo Group Limited||Aerosol formulations containing P134a and salbutamol|
|US5674472 *||May 19, 1995||Oct 7, 1997||Glaxo Group Limited||Canisters containing aerosol formulations containing P134a and fluticasone propionate|
|US5676929 *||May 19, 1995||Oct 14, 1997||Glaxo Group Limited||Canister containing aerosol formulations containing P134a and particulate medicaments|
|US5683676 *||May 19, 1995||Nov 4, 1997||Glaxo Group Limited||Canister containing aerosol formulations containing P134a and particulate medicaments|
|US5736124 *||May 30, 1995||Apr 7, 1998||Glaxo Group Limited||Aerosol formulations containing P134a and particulate medicament|
|US5744123 *||Jun 5, 1995||Apr 28, 1998||Glaxo Group Limited||Aerosol formulations containing P134a and particulate medicaments|
|US5817293 *||May 30, 1995||Oct 6, 1998||Glaxo Group Limited||Canister containing aerosol formulations containing P134a and particulate medicaments|
|US5839429 *||Aug 20, 1997||Nov 24, 1998||Astra Aktiebolag||Method and apparatus in connection with an inhaler|
|US5916540 *||Apr 6, 1998||Jun 29, 1999||Glaxo Group Limited||Aerosol formulations containing P134A and/or P227 and particulate medicament|
|US5922306 *||Apr 15, 1998||Jul 13, 1999||Glaxo Group Limited||Aerosol formulations containing P134a and particulate medicament|
|US5976573 *||Jul 3, 1996||Nov 2, 1999||Rorer Pharmaceutical Products Inc.||Aqueous-based pharmaceutical composition|
|US5993805 *||Jun 7, 1995||Nov 30, 1999||Quadrant Healthcare (Uk) Limited||Spray-dried microparticles and their use as therapeutic vehicles|
|US6143329 *||May 20, 1999||Nov 7, 2000||Rorer Pharmaceutical Products Inc.||Aqueous-based pharmaceutical composition|
|US6200549||Mar 9, 1999||Mar 13, 2001||Glaxo Group Limited||Aerosol formulation containing P134a and particulate medicament|
|US6221339||May 10, 1999||Apr 24, 2001||Glaxo Group Limited||Medicaments|
|US6238647||Nov 2, 1999||May 29, 2001||Glaxo Group Limited||Aerosol formulations containing salmeterol xinafoate, an anticholinergic agent and tetrafluoroethane|
|US6251368||Jun 17, 1997||Jun 26, 2001||Glaxo Group Limited||Pharmaceutical aerosol formulation containing a particulate medicament, a propellant and substantially free of a surfactant|
|US6293279||Apr 7, 1999||Sep 25, 2001||Trudell Medical International||Aerosol medication delivery apparatus and system|
|US6303103||Jun 14, 2000||Oct 16, 2001||Glaxo Group Limited||Aerosols containing salmeterol xinafoate and an anticholinergic medicament|
|US6306369||Apr 28, 2000||Oct 23, 2001||Glaxo Group Limited||Aerosol formulations containing P134a and particulate medicament|
|US6333023||May 1, 2000||Dec 25, 2001||Glaxo Group Limited||Aerosol formulation containing particulate formoterol, propellant and polar cosolvent|
|US6345617||Sep 26, 1997||Feb 12, 2002||1263152 Ontario Inc.||Aerosol medication delivery apparatus and system|
|US6435177||Aug 15, 2001||Aug 20, 2002||Trudell Medical International||Aerosol medication delivery apparatus and system|
|US6709650||Aug 25, 1999||Mar 23, 2004||Elam Drug Delivery Limited||Spray-dried microparticles and their use as therapeutic vehicles|
|US6743413||May 31, 1995||Jun 1, 2004||3M Company||Suspension aerosol formulations|
|US6893628||Mar 31, 2003||May 17, 2005||Glaxo Group Limited||Aerosol formulations containing P134a and particulate medicament|
|US6919069||Apr 30, 2003||Jul 19, 2005||Glaxo Group Limited||Aerosol formulation containing particulate formoterol, propellant and polar cosolvent|
|US7025058||Apr 26, 2002||Apr 11, 2006||New England Pharmaceuticals, Inc.||Metered dose delivery device for liquid and powder agents|
|US7101534||May 31, 1995||Sep 5, 2006||3M Innovative Properties Company||Suspension aerosol formulations|
|US7105152||May 31, 1995||Sep 12, 2006||3M Innovative Properties Company||Suspension aerosol formulations|
|US7498020||Nov 23, 2004||Mar 3, 2009||Glaxo Group Limited||Medicaments|
|US7562656||Jul 21, 2009||Hydrate, Inc.||Aerosol medication inhalation system|
|US7582284||Apr 14, 2003||Sep 1, 2009||Nektar Therapeutics||Particulate materials|
|US7977045||Jul 12, 2011||Aventis Pharmaceuticals Inc.||Aqueous-based pharmaceutical composition|
|US7994197||Aug 9, 2011||Map Pharmaceuticals, Inc.||Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile|
|US8074641||Dec 11, 2008||Dec 13, 2011||Pre Holdings, Inc.||Aerosol medication inhalation system|
|US8080236||Dec 20, 2011||Nektar Therapeutics Uk, Ltd||Particulate materials|
|US8119639||Jul 19, 2010||Feb 21, 2012||Map Pharmaceuticals, Inc.||Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile|
|US8123761 *||Oct 14, 2005||Feb 28, 2012||Meda Ab||Device for removing a tick|
|US8137657 *||May 16, 2003||Mar 20, 2012||Vectura Limited||Carrier particles for use in dry powder inhalers|
|US8148377||Feb 11, 2008||Apr 3, 2012||Map Pharmaceuticals, Inc.||Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile|
|US8365725 *||Sep 12, 2005||Feb 5, 2013||Oriel Therapeutics, Inc.||Dry powder inhalers that inhibit agglomeration, related devices and methods|
|US8366722 *||Feb 5, 2013||Meda Ab||Method for removing a tick|
|US8459252||Jun 11, 2013||Pari Innovative Manufacturers, Inc.||Aerosol medication inhalation system|
|US8470301||Nov 11, 2011||Jun 25, 2013||Nektar Therapeutics||Particulate materials|
|US8828359||Jun 3, 2013||Sep 9, 2014||Nektar Therapeutics||Particulate materials|
|US8973571||May 23, 2013||Mar 10, 2015||Pre Holding, Inc.||Aerosol medication inhalation system|
|US9027551||Jan 4, 2013||May 12, 2015||Oriel Therapeutics, Inc.||Dry powder inhalers that inhibit agglomeration, related devices and methods|
|US9308335||Jan 13, 2015||Apr 12, 2016||Pre Holding, Inc.||Aerosol medication inhalation system|
|US20030015191 *||Apr 26, 2002||Jan 23, 2003||New England Pharmaceuticals, Inc.||Metered dose delivery device for liquid and powder agents|
|US20030143163 *||Mar 11, 2003||Jul 31, 2003||Glaxo Group Limited||Medicaments|
|US20030165437 *||Mar 31, 2003||Sep 4, 2003||Glaxo Group Limited||Aerosos formulations containing P134a and particulate medicament|
|US20030198600 *||Apr 30, 2003||Oct 23, 2003||Glaxo Group Limited||Aerosol formulation containing particulate formoterol, propellant and polar cosolvent|
|US20030202944 *||May 16, 2003||Oct 30, 2003||Vectura Limited||Carrier particles for use in dry powder inhalers|
|US20030223939 *||Apr 14, 2003||Dec 4, 2003||Andreas Kordikowski||Particulate materials|
|US20040197273 *||Apr 9, 2004||Oct 7, 2004||3M Company||Suspension aerosol formulations|
|US20050089477 *||Nov 23, 2004||Apr 28, 2005||Glaxo Group Limited||Medicaments|
|US20050207991 *||May 9, 2005||Sep 22, 2005||Glaxo Group Limited||Aerosol formulations containing P134a and particulate medicament|
|US20050232873 *||Jun 21, 2005||Oct 20, 2005||Glaxo Group Limited||Aerosol formulation containing particulate formoterol, propellant and polar cosolvent|
|US20070031887 *||Oct 16, 2006||Feb 8, 2007||Soo-Il Kim||Aqueous-based pharmaceutical composition|
|US20070253913 *||Mar 13, 2007||Nov 1, 2007||Nahed Mohsen||Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation|
|US20080127971 *||Sep 12, 2005||Jun 5, 2008||Michael King||Dry Powder Inhalers that Inhibit Agglomeration, Related Devices and Methods|
|US20080287451 *||Feb 11, 2008||Nov 20, 2008||Cook Robert O|
|US20090090355 *||Dec 11, 2008||Apr 9, 2009||Pari Innovative Manufacturers||Aerosol medication inhalation system|
|US20090188491 *||Jan 16, 2009||Jul 30, 2009||Glaxo Group Limited||Medicaments|
|US20100081664 *||Aug 26, 2009||Apr 1, 2010||Map Pharmaceuticals, Inc.||Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile|
|US20100191252 *||Oct 14, 2005||Jul 29, 2010||Laboratory Tickner B.V.||Device for removing a tick|
|US20100284940 *||Nov 11, 2010||Map Pharmaceuticals, Inc.||Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile|
|US20110171141 *||Jul 14, 2011||Kellerman Donald J||Administration of dihydroergotamine mesylate particles using a metered dose inhaler|
|US20120109153 *||Jan 12, 2012||May 3, 2012||Meda Ab||Method for Removing a Tick|
|USD744636 *||Jun 12, 2013||Dec 1, 2015||Clement Clarke International Limited||Spacer for inhaler|
|USD748242 *||Jul 11, 2014||Jan 26, 2016||H. Stuart Campbell||Inhaler mouthpiece|
|USRE43174||Jan 18, 2007||Feb 14, 2012||Trudell Medical International||Aerosol delivery apparatus|
|USRE45068||Feb 13, 2012||Aug 12, 2014||Trudell Medical International||Aerosol delivery apparatus|
|DE2642174A1 *||Sep 20, 1976||Apr 7, 1977||American Cyanamid Co||Vorrichtung zum abgeben eines aerosols|
|WO1992011048A1 *||Dec 18, 1991||Jul 9, 1992||Healthscan Products, Inc.||Metered dose inhalation unit|
|U.S. Classification||222/182, 128/203.15, 222/402.2|
|International Classification||A61M11/02, A61M15/02, A61M11/00, A61M11/06, A61M11/08, A61M13/00, A61M15/00|
|Cooperative Classification||A61M15/009, A61M2202/064, A61M15/0086|
|European Classification||A61M15/00K, A61M15/00P|